Becton, Dickinson and Company

Equities

BDX

US0758871091

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 01:30:01 16/07/2024 am IST			5-day change	1st Jan Change
226.1 ^USD	-1.32%		+0.24%	-7.28%

10/07	Health Care Up in Anticipation of Deal Activity -- Health Care Roundup	DJ
10/07	FDA Reports Supply Interruptions for Becton Dickinson BD BACTEC Culture Media Bottles	DJ

Health Care Up in Anticipation of Deal Activity -- Health Care Roundup

July 11, 2024 at 01:58 am IST

Health-care companies rose amid anticipation of further deal activity.

The Federal Trade Commission is preparing to sue the largest three pharmacy-benefit managers -- UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts -- over their tactics for negotiating prices for drugs including insulin, after a two-year investigation into whether the companies steer patients away from less-expensive medicines.

Shares of Becton Dickinson rose after the Food and Drug Administration addressed supply issues surrounding blood-culture vials.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

07-10-24 1828ET

Latest news about Becton, Dickinson and Company

Health Care Up in Anticipation of Deal Activity -- Health Care Roundup	11/07	DJ
FDA Reports Supply Interruptions for Becton Dickinson BD BACTEC Culture Media Bottles	10/07	DJ
US FDA flags shortage of Becton Dickinson's blood test tubes	10/07	RE
Becton, Dickinson Says it Exceeded 2023 Emissions Reduction Targets	10/07	MT
Citigroup Adjusts Price Target on Becton, Dickinson to $255 From $260	10/07	MT
Goldman Sachs Adjusts Price Target on Becton, Dickinson to $262 From $274	10/07	MT
Evercore ISI Adjusts Price Target on Becton, Dickinson to $285 From $290, Maintains Outperform Rating	02/07	MT
BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool	26/06	CI
Tandem Diabetes Care, Inc. Appoints Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, Effective June 21, 2024	20/06	CI
Evercore ISI Raises Becton, Dickinson and Company's Price Target to $290 From $282	14/06	MT
Sector Update: Health Care Stocks Steady Premarket Monday	03/06	MT
Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash	03/06	DJ
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Division for $4.2 Billion in Cash	03/06	MT
Edwards Lifesciences to sell critical care products unit to Becton Dickinson for $4.2 bln	03/06	RE
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion	03/06	MT
Becton, Dickinson and Company entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.	03/06	CI
DBS Bank Adjusts Price Target on Becton, Dickinson to $285 From $300	15/05	MT
Transcript : Becton, Dickinson and Company Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM	14/05
Exclusive-Biden to put tariffs on China medical supplies - sources	10/05	RE
Barclays Adjusts Price Target on Becton, Dickinson to $312 From $305, Keeps Overweight Rating	06/05	MT
TD Cowen Adjusts Price Target on Becton, Dickinson and Company to $260 From $271	03/05	MT
Tranche Update on Becton, Dickinson and Company's Equity Buyback Plan announced on November 4, 2021.	03/05	CI
Evercore ISI Raises Becton, Dickinson and Company Price Target to $282 From $280	02/05	MT
Sector Update: Health Care Stocks Mixed Premarket Thursday	02/05	MT
Sector Update: Health Care	02/05	MT

Chart Becton, Dickinson and Company

Duration

Period

More charts

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

01/08/2024 - Q3 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Becton, Dickinson and Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

226.1 USD

Average target price

277.8 USD

Spread / Average Target

+22.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BECTON, DICKINSON AND COMPANY	-7.28%	65.34B
ABBOTT LABORATORIES	-6.46%	179B
MEDTRONIC PLC	-6.43%	98.84B
HOYA CORPORATION	+15.46%	45.41B
DEXCOM, INC.	-8.93%	44.94B
CENCORA, INC.	+8.19%	43.76B
METTLER-TOLEDO INTERNATIONAL, INC.	+12.00%	29.01B
TERUMO CORPORATION	+19.39%	25.65B
WEST PHARMACEUTICAL SERVICES, INC.	-9.09%	23.32B
ZIMMER BIOMET HOLDINGS, INC.	-12.47%	21.92B

Other Medical Equipment, Supplies & Distribution